Vannair Aerosol 160mcg/4.5mcg 120D (Budesonide/Formoterol)

Category

Respiratory Medications

Line

Vannair

Brand

Astrazeneca

Molecule

Budesonide/Formoterol

Presentation

Aerosol 160Mcg/4.5Mcg, 120 doses

Laboratory

Astrazeneca

Indications

Vannair Aerosol is indicated for the treatment and control of chronic obstructive pulmonary disease (COPD) and asthma in patients requiring combined therapy with a corticosteroid and a long-acting bronchodilator. This medication helps reduce inflammation and open airways, facilitating breathing. Its use is recommended for patients with persistent symptoms that are not adequately controlled with an inhaled corticosteroid alone. Vannair administration should be as directed by the treating physician, who will assess the need and frequency of use according to the patient's condition.

Composition

Each dose of aerosol contains 160 mcg of Budesonide and 4.5 mcg of Formoterol in a propellant solution. Excipients include components such as cetyl alcohol, propylene glycol, among others, which facilitate the aerosol formulation. It is important to review the complete list of ingredients to avoid adverse reactions in case of known allergies.

Contraindications

Vannair is contraindicated in patients with known hypersensitivity to any of the components of the formula, as well as in those presenting an acute asthma or COPD episode requiring immediate medical attention. It should not be used as a rescue treatment during an asthmatic crisis.

Precautions

Caution is advised in patients with a history of cardiovascular disease, hypertension, diabetes mellitus, and thyroid disorders. Regular medical follow-up is essential to adjust therapy according to the patient's response and avoid adverse effects.

Storage

Store in a cool, dry place, protected from direct light. Keep out of reach of children. Do not expose to temperatures above 30°C. Avoid freezing.

Consult your doctor.

Prescription required.